Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives.

Cells · 2026 · PMC13406534 · PMID 42505401

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Treatment with elafibranor 120 mg/day showed a favorable trend toward MASH resolution without worsening fibrosis, as confirmed by liver biopsy, while also improving lipid profile, insulin sensitivity, liver enzymes, and inflammatory markers [ 135 ].

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.